A New Frontier for Discovery – How 3D genomics reveals novel disease mechanisms and therapeutic targets missed by other technologies
In this session, Anthony Schmitt, PhD, SVP of Science at Arima Genomics, and Matija Snuderl, MD, of NYU Langone Health and School of Medicine, share the results of their collaboration and examples of how 3D genomics is revealing genetic drivers of previously undiagnosed tumors, reshaping how we understand disease, and producing exciting new opportunities in cancer research and beyond. Learn how 3D genomics is enabling biomarker discovery, tumor classification, and patient stratification.
Uncovering gene fusions with 3D genomics: from clinical validation to actionable insights for undiagnosable solid tumors
Anthony Schmitt, PhD, Arima Genomics + Matija Snuderl, MD, NYU Langone Health and School of Medicine
Saturday, November 5 | 9:15 am – 10:15 am
Poster Location: ST065 | Exhibit/Poster Hall
Meet the Speakers:
Anthony Schmitt, PhDSVP, Science at Arima Genomics
Anthony Schmitt, PhD has led the development of the core Arima Hi-C chemistry and technology platform since Arima’s inception, contributed to core inventions and technology development grants, and continues to lead the R&D programs for targeted chromosome conformation capture techniques.
Matija Snuderl, MDNYU Langone Health and School of Medicine
Dr. Matija Snuderl is a neuropathologist at NYU Langone whose clinical research focuses on identifying novel biomarkers for diagnosis and therapy. Dr. Snuderl's laboratory at NYU Langone studies cancer genetics and epigenetics and examines the molecular differences between tumors at the cellular level.